RecruitingNot a traditional drug phaseobservationalRules rewrite

ASSESS ALL ALS Study

The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control cohorts. This consortium is being funded by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) and managed by two clinical coordinating centers (CCC) at Barrow Neurological Institute and Massachusetts General Hospital.

Official registry: https://clinicaltrials.gov/study/NCT06578195 · St. Joseph's Hospital and Medical Center, Phoenix · enrollment listed as 2,000

What this phase means

This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.

They plan to enroll about 2,000 people at 37 sites. Taking part typically means study visits and measurements plus check-ins.

Official title (unrewritten)

ASSESS ALL ALS - Longitudinal Biomarker Study for Symptomatic ALS and Control Participants

Primary outcome (registry wording): ALS Functional Rating Scale-Revised (ALSFRS-R)

Who it is for (from inclusion criteria)

Ages 18 Years to any
for ALS participants:
Age 18 years or older
Willing to follow study procedures
Diagnosis of ALS by a physician
Access to a smartphone, computer or tablet, and internet (need not be in the home - access to a public library or other available computer with internet connection is sufficient)
who can join for control participants:
No diagnosis of ALS , Progressive Muscular Atrophy (PMA) or Primary Lateral Sclerosis (PLS)

Who the registry excludes

for all participants:

Public study contact (from the registry)

ALL ALS Patient Navigator

602-845-0248

info@all-als.org

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

37 listed

University of Alabama Birmingham — Birmingham, Alabama (recruiting)
Barrow Neurological Institute — Phoenix, Arizona (recruiting)
University of California, Irvine — Irvine, California (recruiting)
University of California San Diego — La Jolla, California (recruiting)
University of California, Los Angeles — Los Angeles, California (recruiting)
University of California, San Francisco — San Francisco, California (recruiting)
University of Colorado Anschutz Medical Campus — Aurora, Colorado (recruiting)
Hospital For Special Care — New Britain, Connecticut (recruiting)
Georgetown University — Washington D.C., District of Columbia (recruiting)
Nova Southeastern University — Davie, Florida (recruiting)
Mayo Clinic — Jacksonville, Florida (recruiting)
Saint Alphonsus Regional Medical Center — Boise, Idaho (recruiting)

+ 1 sites outside the US on the same record

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland

Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Re…

We will investigate the clinical manifestations and molecular genetic defects of heritable urologic malignant disorders. Families with urologic malignancy with known or suspected genetic basis will be enrolled.

NCT00001238 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

RecruitingNot a traditional drug phaseBethesda, Maryland

Study of Systemic Lupus Erythematosus

This protocol will evaluate patients with systemic lupus erythematosus (SLE) and their relatives to learn more about how the disease develops and changes over time. It will also study genetic factors that make a person susceptible to SLE.

NCT00001372 · Official ClinicalTrials.gov record · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

RecruitingNot a traditional drug phaseWashington D.C., District of Columbia

Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics

This study is designed to explore the genetics and pathophysiology of diseases presenting with intermittent fever, including familial Mediterranean fever, TRAPS, hyper-IgD syndrome, and related diseases. The following individuals may be eligible for this natural history study: 1) patients with known or suspected familial Mediterranean fever, TRAPS, hyper-IgD syndrome or related disorders; 2) relatives of these patients; 3) healthy, normal volunteers 7 years of age or older.

NCT00001373 · Official ClinicalTrials.gov record · National Human Genome Research Institute (NHGRI)

FAQ about this NCT record

Is NCT06578195 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT06578195?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT06578195?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary